Helicobacter pylori infection in India: The case against eradication

Indian Journal of Gastroenterology

Volumn 25, Issue 1, 2006, Pages 25-28

  Ramakrishna, B S ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; FURAZOLIDONE; LANSOPRAZOLE; METRONIDAZOLE; PROTON PUMP INHIBITOR; SUCRALFATE; TETRACYCLINE; TINIDAZOLE;

BACTERIAL INFECTION; CANCER RISK; CLINICAL TRIAL; DRUG SENSITIVITY; DUODENUM ULCER; DYSPEPSIA; ERADICATION THERAPY; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; INCIDENCE; MEDICAL PRACTICE; META ANALYSIS; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PATHOGENESIS; PRACTICE GUIDELINE; REVIEW; RISK REDUCTION; STOMACH ULCER; SYSTEMATIC REVIEW; TREATMENT INDICATION; ESOPHAGITIS; HELICOBACTER INFECTION; INDIA; MICROBIOLOGY; PREVALENCE; STOMACH TUMOR;

DUODENAL ULCER; DYSPEPSIA; ESOPHAGITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INDIA; PREVALENCE; STOMACH NEOPLASMS;

EID: 33744493677     PISSN: 02548860     EISSN: 02548860     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Graham DY, Adam E, Reddy GT, Agarwal JP, Agarwal R, Evans DJ Jr, et al. Seroepidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries. Dig Dis Sci 1991;36:1084-8.
2. Gill HH, Majumdar P, Shankaran K, Desai HG. Age-related prevalence of H. pylori antibodies in Indian subjects. Indian J Gastroenterol 1994;13:92-4.
3. Kang G, Rajan DP, Patra S, Chacko A, Mathan MM. Use of serology, the urease test and histology in diagnosis of Helicobacter pylori infection in symptomatic and asymptomatic Indians. Indian J Med Res 1999;110:86-90.
4. Jais M, Barua S. Seroprevalence of anti Helicobacter pylori IgG/IgA in asymptomatic population from Delhi. J Commun Dis 2004;36:132-5.
5. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65-9.
6. Prasad S, Mathan M, Chandy G, Rajan DP, Venkateswaran S, Ramakrishna BS, et al. Prevalence of Helicobacter pylori in southern Indian controls and patients with gastroduodenal disease. J Gastroenterol Hepatol 1994;9:501-6.
7. Marshall BJ, Goodwin CS, Warren JR, Murray R, Blincow ED, Blackbourn SJ, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori . Lancet 1988;2:1437-42.
8. Ford A, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2004;(4):CD003840.
9. Dayal VM, Kumar P, Kamal J, Shahi SK, Agrawal BK. Triple-drug therapy of Helicobacter pylori infection in duodenal ulcer disease. Indian J Gastroenterol 1997;16:46-8.
10. Ahuja V, Dhar A, Bal C, Sharma MP. Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country. Aliment Pharmacol Ther 1998;12:551-5.
11. Nanivadekar SA, Sawant PD, Patel HD, Shroff CP, Popat UR, Bhatt PP. Association or peptic ulcer with Helicobacter pylori and the recurrence rate. A three year follow up study. J Assoc Physicians India 1990;38 (Suppl 1):703-6.
12. Parsonnet J, Forman D. Helicobacter pylori infection and gastric cancer - for want of more outcomes. JAMA 2004;291:244-5.
13. Greenberg ER, Alberts DS, Potter JD. What should we now do about H. pylori ? Cancer Epidemiol Biomarkers Prev 2005;14:1851-2.
14. Ho KY, Chan YH, Kang JY. Increasing trend of reflux esophagitis and decreasing trend of Helicobacter pylori infection in patients from a multiethnic Asian country. Am J Gastroenterol 2005;100:1923-8.
15. Raghunath AS, O'Morain C, McLoughlin RC. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther 2005;22(Suppl 1):55-63.
16. Jensen RT. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 2006;98:4-19.
17. Delaney B, McColl K. Review article: Helicobacter pylori and gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005;22(Suppl 1):32-40.
18. Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005;(1):CD002096.
19. Dhali GK, Garg PK, Sharma MP. Role of anti- Helicobacter pylori treatment in H. pylori -positive and cytoprotective drugs in H. pylori -negative, non-ulcer dyspepsia: results of a randomised, double-blind, controlled trial in Asian Indians. J Gastroenterol Hepatol 1999;14:523-8.
20. Scottish Intercollegiate Guidelines Network. Dyspepsia: a national clinical guideline. ISBN 1 899893 68 7. Edinburgh: Royal College of Physicians. 2003.
21. Fock KM, Guan YK, Chian LC, Luman W, Nam ACE, Kang JPS. Management of Helicobacter pylori infection. Singapore: Ministry of Health. 2004.
22. Talley NJ, Vakil N. Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005;100:2324-37.
23. Delaney BC, Moayyedi P, Forman D. Initial management strategies for dyspepsia. Cochrane Database Syst Rev 2003;(2):CD001961.
24. Thyagarajan SP, Ray P, Das BK, Ayyagari A, Khan AA, Dharmalingam S, et al. Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: multicentric study. J Gastroenterol Hepatol 2003;18:1373-8.
25. Datta S, Chattopadhyay S, Patra R, De R, Ramamurthy T, Hembram J, et al. Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy. Aliment Pharmacol Ther 2005;22:51-7.
26. Bhasin DK, Sharma BC, Sinha SK, Ray P, Vaiphei K, Singh K. Helicobacter pylori eradication: comparison of three treatment regimens in India. J Clin Gastroenterol 1999;28:348-51.
27. Bhasin DK, Sharma BC, Ray P, Pathak CM, Singh K. Comparison of seven and fourteen days of lansoprazole, clarithromycin, and amoxicillin therapy for eradication of Helicobacter pylori : a report from India. Helicobacter 2000;5:84-7.
28. Bapat MR, Abraham P, Bhandarkar PV, Phadke AY, Joshi AS. Acquisition of Helicobacter pylori infection and reinfection after its eradication are uncommon in Indian adults. Indian J Gastroenterol 2000;19:172-4.
29. Pai CG, Thomas CP, Biswas A, Rao S, Ramnarayan K. Quadruple therapy for initial eradication of Helicobacter pylori in peptic ulcer: comparison with triple therapy. Indian J Gastroenterol 2003;22:85-7.
30. Bhatia V, Ahuja V, Das B, Bal C, Sharma MP. Use of imidazole-based eradication regimens for Helicobacter pylori should be abandoned in North India regardless of in vitro antibiotic sensitivity. J Gastroenterol Hepatol 2004;19:619-25.
31. Borody TJ, Andrews P, Mancuso N, McCauley D, Jankiewicz E, Ferch N, et al. Helicobacter pylori reinfection rate in patients with cured duodenal ulcer. Am J Gastroenterol 1994;89:529-32.
32. Ford AC, Forman D, Bailey AG, Axon AT, Moayyedi P. A community screening program for Helicobacter pylori saves money: 10-year follow-up of a randomized controlled trial. Gastroenterology 2005;129:1910-7.
33. Blaser MJ. Helicobacters are indigenous to the human stomach: duodenal ulceration is due to changes in gastric microecology in the modern era. Gut 1998;43:721-7.
34. Blaser MJ. Helicobacter pylori eradication and its implications for the future. Aliment Pharmacol Ther 1997;11(Suppl 1):103-7.
35. Blaser MJ, Atherton JC. Helicobacter pylori persistence: biology and disease. J Clin Invest 2004;113:321-33.
36. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002;347:911-20.